OverviewSuggest Edit

Cerecor is a clinical-stage biopharmaceutical company, which develops drugs to treat patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

TypePublic
Founded2011
HQBaltimore, US
Websitecerecor.com

Latest Updates

Employees (est.) (Dec 2018)64(+69%)
Revenue (FY, 2018)$18.3 M
Share Price (Jun 2019)$5 (+3%)

Key People/Management at Cerecor

Peter Greenleaf

Peter Greenleaf

CEO
Matthew V. Phillips

Matthew V. Phillips

Chief Commercial Officer
Perry Calias

Perry Calias

Chief Scientific Officer
Show more

Cerecor Office Locations

Cerecor has an office in Baltimore
Baltimore, US (HQ)
400 E Pratt St #606
Show all (1)

Cerecor Financials and Metrics

Cerecor Revenue

Cerecor's revenue was reported to be $18.33 m in FY, 2018
USD

Revenue (Q1, 2019)

5.4m

Gross profit (Q1, 2019)

3.5m

Gross profit margin (Q1, 2019), %

64%

Net income (Q1, 2019)

(7.5m)

EBIT (Q1, 2019)

(7.0m)

Market capitalization (10-Jun-2019)

212.9m

Closing stock price (10-Jun-2019)

5.0

Cash (31-Mar-2019)

16.1m

EV

211.1m
Cerecor's current market capitalization is $212.9 m.
Annual
USDFY, 2015FY, 2016FY, 2018

Revenue

18.3m

Cost of goods sold

7.5m

Gross profit

10.8m

Gross profit Margin, %

59%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

25.0m4.8m4.1m5.4m

Cost of goods sold

863.6k1.4m3.1m1.9m

Gross profit

3.4m963.5k3.5m

Gross profit Margin, %

70%24%64%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

21.2m5.1m2.5m10.6m

Accounts Receivable

3.3m3.2m

Inventories

401.6k391.3k382.2k1.1m

Current Assets

21.6m5.7m11.0m21.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

3.3m16.6m11.9m8.8m3.0m5.5m24.0m2.5m2.2m6.8m16.1m

Accounts Receivable

2.8m3.3m3.0m2.7m

Inventories

3.4m1.5m1.1m1.0m

Current Assets

3.4m16.9m13.1m9.5m3.5m6.0m28.1m13.4m11.8m18.5m26.7m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(10.5m)(16.5m)11.9m

Depreciation and Amortization

23.5k26.9k425.5k

Inventories

2.7m

Accounts Payable

(268.7k)332.1k96.1k
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(6.8m)(5.1m)(8.7m)(14.8m)(2.0m)(3.8m)15.0m(3.9m)(9.9m)(34.5m)(7.5m)

Depreciation and Amortization

17.4k6.8k13.4k20.5k5.8k11.7k17.1k1.0m2.3m3.3m1.1m

Accounts Payable

318.2k(71.4k)61.2k109.9k(414.3k)(682.9k)(697.7k)1.9m1.6m172.2k(196.7k)

Cash From Operating Activities

(6.6m)(3.7m)(7.4m)(10.9m)(2.2m)(4.0m)15.1m(280.4k)(614.1k)(1.2m)(3.1m)
USDY, 2019

EV/EBIT

-21.5 x

EV/CFO

-48.4 x

Financial Leverage

3.2 x
Show all financial metrics

Cerecor Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Ichorion TherapeuticsSeptember 28, 2018$27 m

Cerecor Online and Social Media Presence

Embed Graph

Cerecor News and Updates

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

Shares of Cerecor Inc. rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a rare metabolic disorder. The FDA has granted Rockville…

Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency

ROCKVILLE, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administr…

Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)

ROCKVILLE, Md., July 01, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its completed P…

Cerecor Added to Russell 3000® Index

ROCKVILLE, Md., June 28, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the Russell…

Cerecor Set to Join Russell 3000® Index

ROCKVILLE, Md., June 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Russell 30…

Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers

ROCKVILLE, Md., April 29, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has completed dosing in a Ph…
Show more

Cerecor Blogs

Cerecor Reports Second Quarter 2019 Results

-Positive Final Results with CERC-301 in nOH-First Patient Enrolled in CDG FIRST Trial- FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commerc…

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG

ROCKVILLE, Md., July 29, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has received notification fro…

Cerecor Announces First Patient Enrolled in CDG FIRST Trial

-A Retrospective Study on Congenital Disorders of Glycosylation ROCKVILLE, Md., July 15, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics an…

Cerecor Appoints Keith Schmidt to its Board of Directors

ROCKVILLE, Md., June 12, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to …

Cerecor Reports First Quarter 2019 Results

- Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers ROCKVILLE, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in developme…

Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)

ROCKVILLE, MD / ACCESSWIRE / April 15, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive interim results from the Phase I s…
Show more

Cerecor Frequently Asked Questions

  • When was Cerecor founded?

    Cerecor was founded in 2011.

  • Who are Cerecor key executives?

    Cerecor's key executives are Peter Greenleaf, Matthew V. Phillips and Perry Calias.

  • How many employees does Cerecor have?

    Cerecor has 64 employees.

  • What is Cerecor revenue?

    Latest Cerecor annual revenue is $18.3 m.

  • What is Cerecor revenue per employee?

    Latest Cerecor revenue per employee is $286.4 k.

  • Who are Cerecor competitors?

    Competitors of Cerecor include Opiant Pharmaceuticals, Mylan and Amphastar Pharmaceuticals.

  • Where is Cerecor headquarters?

    Cerecor headquarters is located at 400 E Pratt St #606, Baltimore.

  • Where are Cerecor offices?

    Cerecor has an office in Baltimore.

  • How many offices does Cerecor have?

    Cerecor has 1 office.